CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Pipeline Analysis
3.2.2.Top winning strategies
3.2.3.Top player positioning
3.3.Key forces shaping the global neutropenia treatment market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in prevalence of leukemia
3.4.1.2.Surge in R&D efforts and development of new drugs
3.4.1.3.Fundamental shift from branded drugs to biosimilars in cancer supportive treatment
3.4.2.Restraints
3.4.2.1.High cost of the treatment of neutropenia
3.4.2.2.Stringent rules and regulations for product approvals
3.4.3.Opportunity
3.4.3.1.Robust drug pipeline for neutropenia treatment
3.5.Standard of Care for Neutropenia treatment and recommended guidelines
CHAPTER 4:GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT
4.1.Overview
4.1.1.Market size and forecast
4.2.Colony-stimulating factors (CSFs)
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Antibiotics
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Antifungals
4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Antivirals
4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital Pharmacies
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Retail Pharmacies
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online Pharmacies
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by treatment
6.2.3.Market size and forecast, by distribution channel
6.2.4.Market size and forecast, by country
6.2.4.1.U.S.
6.2.4.2.Purchasing/distribution channels in the U.S.
6.2.4.2.1.U.S. market size and forecast, by treatment
6.2.4.2.2.U.S. market size and forecast, by distribution channel
6.2.4.3.Canada
6.2.4.3.1.Canada market size and forecast, by treatment
6.2.4.3.2.Canada market size and forecast, by distribution channel
6.2.4.4.Mexico
6.2.4.4.1.Mexico market size and forecast, by treatment
6.2.4.4.2.Mexico market size and forecast, by distribution channel
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by treatment
6.3.3.Market size and forecast, by distribution channel
6.3.4.Market size and forecast, by country
6.3.4.1.Purchasing/distribution channels in the Europe
6.3.4.2.Germany
6.3.4.2.1.Germany market size and forecast, by treatment
6.3.4.2.2.Germany market size and forecast, by distribution channel
6.3.4.3.France
6.3.4.3.1.France market size and forecast, by treatment
6.3.4.3.2.France market size and forecast, by distribution channel
6.3.4.4.UK
6.3.4.4.1.UK market size and forecast, by treatment
6.3.4.4.2.UK market size and forecast, by distribution channel
6.3.4.5.Italy
6.3.4.5.1.Italy market size and forecast, by treatment
6.3.4.5.2.Italy market size and forecast, by distribution channel
6.3.4.6.Spain
6.3.4.6.1.Spain market size and forecast, by treatment
6.3.4.6.2.Spain market size and forecast, by distribution channel
6.3.4.7.Rest of Europe
6.3.4.7.1.Rest of Europe market size and forecast, by treatment
6.3.4.7.2.Rest of Europe market size and forecast, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by treatment
6.4.3.Market size and forecast, by distribution channel
6.4.4.Market size and forecast, by country
6.4.4.1.Japan
6.4.4.1.1.Purchasing/distribution channels in the Japan
6.4.4.1.2.Japan market size and forecast, by treatment
6.4.4.1.3.Japan market size and forecast, by distribution channel
6.4.4.2.China
6.4.4.2.1.China market size and forecast, by treatment
6.4.4.2.2.China market size and forecast, by distribution channel
6.4.4.3.Australia
6.4.4.3.1.Australia market size and forecast, by treatment
6.4.4.3.2.Australia market size and forecast, by distribution channel
6.4.4.4.India
6.4.4.4.1.India market size and forecast, by treatment
6.4.4.4.2.India market size and forecast, by distribution channel
6.4.4.5.Rest of Asia-Pacific
6.4.4.5.1.Rest of Asia-Pacific market size and forecast, by treatment
6.4.4.5.2.Rest of Asia-Pacific market size and forecast, by distribution channel
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by treatment
6.5.3.Market size and forecast, by distribution channel
6.5.4.Market size and forecast, by country
6.5.4.1.Brazil
6.5.4.1.1.Brazil market size and forecast, by treatment
6.5.4.1.2.Brazil market size and forecast, by distribution channel
6.5.4.2.Saudi Arabia
6.5.4.2.1.Saudi Arabia market size and forecast, by treatment
6.5.4.2.2.Saudi Arabia market size and forecast, by distribution channel
6.5.4.3.South Africa
6.5.4.3.1.South Africa market size and forecast, by treatment
6.5.4.3.2.South Africa market size and forecast, by distribution channel
6.5.4.4.Rest of LAMEA
6.5.4.4.1.Rest of LAMEA market size and forecast, by treatment
6.5.4.4.2.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.AMGEN INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BEYONDSPRING INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.CELLERANT THERAPEUTICS, INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Key strategic moves and developments
7.4.KYOWA KIRIN
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.MYLAN N.V.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.NOVARTIS AG
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.PARTNER THERAPEUTICS, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Key strategic moves and developments
7.8.PFIZER INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SPECTRUM PHARMACEUTICALS, INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.11.COHERUS BIOSCIENCES, INC.
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.11.6.Key strategic moves and developments
